We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWith many anticipated new medicines for rare diseases, countries are beginning to prepare appropriat...
Read moreLast month, EMA published its overview of key recommendations for 2020 on the authorisation and safe...
Read moreOur experts predict the 5 trends they think will dominate the European pricing and market access lan...
Read moreBy joining together, countries can combine their resources to potentially increase the efficiency of...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreFaster access to new treatments for very rare conditions announced following a revised decision maki...
Read moreOver the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read more